July 24, 2025Journal of Chromatographic Science

Optimized Simultaneous Estimation of Metformin, Teneligliptin, and Pioglitazone in Tablet and Bulk Drug: A Box–Behnken Design Approach for RP-UFLC Method Development and Validation

View Full Paper

Ask AI

Bookmark

Authors

JPJignesh Panchal JDJayesh Dhalani

Discussion

Member takes

Implication

Analytical method quantifies metformin, teneligliptin, and pioglitazone in drug formulations, suggesting a new approach in treatment for type 2 diabetes.

Key Points

The developed method achieves an impressive runtime of just 3.0 minutes for three medications.
Quantification limits were established at 0.209 μg/mL for metformin, 0.712 μg/mL for teneligliptin, and 57.030 μg/mL for pioglitazone.
Utilizing a Box–Behnken design enabled optimization of the reversed phase ultra-fast liquid chromatography method.
Method validation adhered to rigorous guidelines, ensuring accuracy, precision, and reliability.

Cite This Study

Panchal et al. (2025) studied this question.

synapsesocial.com/papers/68af3e3ccf1dd9ea359eb0a5 https://doi.org/10.1093/chromsci/bmaf045

View Full Paper

Ask AI

Bookmark

Implication

Analytical method quantifies metformin, teneligliptin, and pioglitazone in drug formulations, suggesting a new approach in treatment for type 2 diabetes.

Optimized Simultaneous Estimation of Metformin, Teneligliptin, and Pioglitazone in Tablet and Bulk Drug: A Box–Behnken Design Approach for RP-UFLC Method Development and Validation

Discussion

Member takes

Implication

Key Points

Cite This Study

Optimized Simultaneous Estimation of Metformin, Teneligliptin, and Pioglitazone in Tablet and Bulk Drug: A Box–Behnken Design Approach for RP-UFLC Method Development and Validation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider